Speed is critical in antibody drug development. Researchers need rapid access to high-quality proteins for characterization and decision-making, yet protein production often remains a bottleneck. Conventional CHO-based transient expression workflows can require two weeks or longer, slowing candidate evaluation and delaying project timelines.
GenScript’s TurboCHO™ Protein Expression Kit is designed to help researchers move faster. Built around a newly developed CHO K1 cell line, the all-in-one system combines cells, plasmids, chemically defined serum-free medium, and transfection reagents into a streamlined workflow that enables recombinant protein harvest in as little as 3–7 days. Compared with conventional CHO-based transient expression workflows that can require two weeks or longer, TurboCHO™ helps significantly shorten the timeline from construct design to experimental results.
Fast turnaround is only valuable if performance is maintained. In comparative studies, TurboCHO™ achieved expression titers at Day 5 that matched or exceeded titers typically observed at Day 10. Across multiple antibody formats, TurboCHO™ generated higher Day 7 titers than a competing expression kit at Day 10 while maintaining protein purity. By delivering actionable expression data sooner, the system helps reduce delays between development milestones and accelerates candidate evaluation.
The kit is broadly compatible with IgG, bispecific antibodies, and other challenging proteins. It supports applications ranging from high-throughput screening to shake flasks and bioreactors, providing a scalable workflow from early research through process development and scale-up.
By reducing expression timelines from weeks to days while maintaining strong yields and broad molecule compatibility, the TurboCHO™ Protein Expression Kit helps researchers generate high-quality proteins faster and accelerate antibody drug development. For teams looking for additional capacity, or a fully outsourced solution, GenScript's TurboCHO™ protein expression services extend the same platform advantages beyond the lab bench, providing flexible options to support different project needs in as short as 5 days from gene to antibody.